<DOC>
	<DOCNO>NCT02243657</DOCNO>
	<brief_summary>The study investigate safe ASP3652 well tolerate take multiple dos . The study also assess quickly extent absorb eliminate body . In addition , effect age gender investigate . The study consist two part . In Part 1 four dose level administer four separate group initially . Two additional dosage investigate . Subjects receive either once-daily dose ( QD ) twice-daily dose ( BID ) ASP3652 placebo . Part 2 performed one group elderly healthy male female ( post-menopausal ) subject . Subjects receive either twice daily dose ( BID ) ASP3652 placebo . For part study , subject stay clinic one period 18 day .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Effects Body Healthy Young Elderly Male Female Subjects Ascending Multiple Oral Doses ASP3652</brief_title>
	<detailed_description>This Multiple Ascending Dose ( MAD ) study two part . Screening part take place Days -28 -3 . Subjects admit clinic Day -2 , discharge Day 16 . They return End Study Visit ( ESV ) 7 14 day ( early ) discharge . Part 1 evaluates safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) ASP3652 follow ascend multiple oral dos . The initially plan four dose level match placebo give four separate group . Thereafter two additional dosage level investigate . All group receive single dose ASP3652 administer morning Day 1 Day 14 , twice-daily dos administer Day 2 Day 13 fast condition , except last group receive dosage daily Day 1 Day 14 . Part 2 evaluates safety , tolerability , PK PD ASP3652 follow ascend multiple oral dos healthy elderly male female subject . This part contain single , placebo-controlled group . All subject receive twice daily dos administration base result Part 1 . All subject part receive train Neurocognitive Test Battery ( NTB ) test monitor psychotropic effect .</detailed_description>
	<criteria>Body Mass Index ( BMI ) 18.530.0 kg/m2 male female subject . Male subject nonfertile , i.e . surgically sterilized practice adequate contraceptive method prevent pregnancy . Female subject nonchild bearing potential , i.e . post menopausal , surgically sterilize , hysterectomy medical history , practice adequate ( double barrier ) nonhormonal contraceptive method prevent pregnancy . Pregnant breast feeding within 6 month screen assessment . Presence history clinically significant psychiatric disorder mania , depression schizophrenia . Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>ASP3652</keyword>
	<keyword>Age</keyword>
	<keyword>Gender</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Multiple Ascending Doses ( MAD )</keyword>
</DOC>